FUJIFILM Diosynth Biotechnologies, a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the extension of its gene therapy and viral vaccine Fill/Finish capabilities to provide services in support of late phase candidates and commercial supply.
Fujifilm has invested in Vanrx Pharmasystems’ SA25 Aseptic Filling Workcell gloveless isolator technology with automated environmental monitoring and no glass to glass contact.
Fujifilm’s fill finish services offer rapid changeover between drug products and containers, production predictability and the ability to scale up to support commercial production, even when filling and stoppering complex drug products while minimizing defect rates to maximize yield, which is of critical importance when filling very high value products. These extended Fill/Finish services will be provided from Fujifilm’s state of the art Flexible Biomanufacturing Facility located in College Station, Texas. This facility is a Center of Excellence for Advanced Therapies production.
Fujifilm has locations in Billingham and Redcar, UK, RTP, North Carolina and College Station, Texas. Fujifilm Diosynth has over twenty five years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems.